Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Decatur, GA
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Atlanta, GA
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Covington, LA
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Covington, LA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Portland, ME
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Portland, ME
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Detroit, MI
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Lincoln, NE
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Nashua, NH
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Nashua, NH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Elizabeth, NJ
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Elizabeth, NJ
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Staten Island, NY
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Greensboro, NC
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Greensboro, NC
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Wilmington, NC
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Wilmington, NC
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Columbus, OH
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Gallipolis, OH
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Gallipolis, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Akron, OH
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Perrysburg, OH
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Perrysburg, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Memphis, TN
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Bedford, TX
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Bedford, TX
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
San Antonio, TX
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Wharton, TX
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Wharton, TX
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Houston, TX
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Temple, TX
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Temple, TX
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Norfolk, VA
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Lewisburg, WV
A Study of the Safety and Efficacy of MK-3102 Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016 AM2)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Lewisburg, WV
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Birmingham, AL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Dothan, AL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Dothan, AL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Muscle Shoals, AL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Phoenix, AZ
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Anaheim, CA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
El Cajon, CA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
El Cajon, CA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Long Beach, CA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Modesto, CA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Modesto, CA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
North Hollywood, CA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
North Hollywood, CA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Norwalk, CA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Norwalk, CA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Pismo Beach, CA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Pismo Beach, CA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
San Diego, CA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Vista, CA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Vista, CA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
West Hills, CA
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
West Hills, CA
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Boca Raton, FL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Boynton Beach, FL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Bradenton, FL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Clearwater, FL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Cocoa, FL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Cocoa, FL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Doral, FL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Doral, FL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Miami, FL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
North Miami, FL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
North Miami, FL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Pembroke Pines, FL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Port Orange, FL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Port Orange, FL
Click here to add this to my saved trials
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  11/12/2013
Clinical Research Facility
mi
from
Tampa, FL
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 11/12/2013
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials